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ABSTRACT 341 WORDS   23 
Importance Due to the susceptibility of observational studies to confounding and reverse 24 
causation, the causal direction and magnitude of the association between telomere length and 25 
incidence of cancer and non-neoplastic diseases is uncertain. 26 
Objective To appraise the causal relevance of telomere length for risk of cancer and non-27 
neoplastic diseases using germline genetic variants as instrumental variables.  28 
Data Sources Genome-wide association studies (GWAS) published up to January 15 2015.  29 
Study Selection GWAS of non-communicable diseases that assayed germline genetic 30 
variation and did not select cohort or control participants on the basis of pre-existing diseases. 31 
Of 163 GWAS of non-communicable diseases identified, 103 shared data for our study. 32 
Data Extraction Summary association statistics for single nucleotide polymorphisms (SNPs) 33 
that are strongly associated with telomere length in the general population.     34 
Main Outcomes Odds ratios (ORs) for disease per 1-SD higher telomere length due to 35 
germline genetic variation. 36 
Results Summary data were available for 35 cancers and 47 non-neoplastic diseases, 37 
corresponding to 409,819 cases (median 2,092 per disease) and 1,404,633 controls (median 38 
7,738 per disease). Increased telomere length due to germline genetic variation was generally 39 
associated with increased risk for site-specific cancers. The strongest associations were 40 
observed for (ORs per 1-SD change in genetically longer telomeres): glioma 5.27  (3.15, 41 
8.81), serous low malignant potential ovarian cancer 4.35 (2.39-7.94); lung adenocarcinoma 42 
3.19 (2.40-4.22); neuroblastoma 2.98 (1.92-4.62); bladder cancer 2.19 (1.32-3.66); melanoma 43 
1.87 (1.55, 2.26); testicular cancer 1.76 (1.02-3.04); kidney cancer 1.55 (1.08-2.23); and 44 
endometrial cancer 1.31 (1.07-1.61). Associations with cancer were stronger for rarer cancers 45 
and tissue sites with lower rates of stem cell division (P<0.05). There was generally little 46 
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evidence of association between genetically longer telomeres and risk of psychiatric, 47 
autoimmune, inflammatory, diabetic and other non-neoplastic diseases, except for coronary 48 
heart disease (0.78 [0.67-0.90]), abdominal aortic aneurysm (0.63 [0.49-0.81]), celiac disease 49 
(0.42 [0.28-0.61]) and interstitial lung disease (0.09 [0.05- 0.15]).  50 
Conclusions Genetically longer telomeres are associated with increased risk for several 51 
cancers, but the relative increase in risk is highly heterogeneous across cancer types, and with 52 
reduced risk for some non-neoplastic diseases, including cardiovascular diseases.   53 
 54 
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INTRODUCTION 68 
 69 
Telomeres are DNA-protein structures at the end of linear chromosomes that protect the 70 
genome from damage, shorten progressively over time in most somatic tissues1 and are 71 
proposed markers of biological ageing. Shorter leukocyte telomeres are correlated with older 72 
age, male sex and other known risk factors for non-communicable diseases2±4 and are 73 
generally associated with higher risk of cardiovascular diseases5,6, type 2 diabetes7 and non-74 
vascular non-neoplastic causes of mortality.6 Whether these associations are causal, however, 75 
is unknown. Telomere length has also been implicated in risk of cancer but the direction and 76 
magnitude of the association is uncertain and contradictory across observational studies.8±12 77 
The uncertainty reflects the considerable difficulty of designing observational studies of 78 
telomere length and cancer incidence that are robust to reverse causation, confounding and 79 
measurement error. For example, it is possible to detect changes in rates of telomere attrition 80 
in cancer cases 3-4 years prior to diagnosis12, suggesting that even well designed prospective 81 
studies may be susceptible to reverse causation. These limitations undermine the potential 82 
clinical application of telomere length as a tool for risk prediction and disease prevention.  83 
The aim of the present report was to conduct a Mendelian randomization study to help clarify 84 
the nature of the association between telomere length and risk of cancer and non-neoplastic 85 
diseases, using germline genetic variants as instrumental variables for telomere length. The 86 
approach, which mimics the random allocation of individuals to the placebo and intervention 87 
arms of a randomized controlled trial, allowed us to: (1) estimate the direction and broad 88 
magnitude of the association of telomere length with risk of multiple cancer and non-89 
neoplastic diseases; (2) appraise the evidence for causality in the estimated etiological 90 
associations; (3) investigate potential sources of heterogeneity in findings for site-specific 91 
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cancers; and (4) compare genetic estimates to findings based on directly measured telomere 92 
length in prospective observational studies.  93 
 94 
METHODS 95 
 96 
Study design 97 
The design of our study, illustrated in Figure S1, had three key components: 1) the 98 
identification of genetic variants to serve as proxies for telomere length; 2) the acquisition of 99 
summary data for the genetic proxies from genome wide association studies (GWASs) of 100 
diseases and risk factors; and 3) the classification of diseases and risk factors into primary or 101 
secondary outcomes based on a priori statistical power. As a first step, we searched the 102 
GWAS catalog13,14 on the 15 January 2015, to identify single nucleotide polymorphisms 103 
(SNPs) associated with telomere length. To supplement the list with additional potential 104 
proxies, we also searched the original study reports curated by the GWAS catalog (using a P 105 
value threshold of 5x10-8).15±23 We acquired summary data for all SNPs identified by our 106 
search from a meta-analysis of GWASs of telomere length, involving 9,190 participants of 107 
European ancestry.16 SNPs initially identified as potential proxies for telomere length were 108 
subsequently excluded if they lacked strong evidence of association with telomere length. We 109 
defined strong evidence of association as a p-value <5x10-8 in: i) the discovery stage of at 110 
least one published GWAS of telomere length15±22 or ii) a meta-analysis of summary data 111 
from Mangino et al16 and other GWASs of telomere length,15,17±22 with any overlapping 112 
studies excluded from Mangino et al.16 We also excluded SNPs with a minor allele frequency 113 
<0.05 or showing strong evidence of between-study heterogeneity in associations with 114 
WHORPHUHOHQJWK3 115 
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The second key component of our design strategy involved the acquisition of summary data, 116 
corresponding to the selected genetic proxies for telomere length, from GWASs of non-117 
communicable diseases and risk factors (Fig. S1). As part of this step, we invited principal 118 
investigators of non-communicable disease studies curated by the GWAS catalog13,14 to share 119 
summary data for our study (see Fig. S1 for further details). We also downloaded summary 120 
data for diseases and risk factors from publically available sources, including study-specific 121 
websites, dbGAP and the GWAS catalog (Fig. S1).  122 
The third key component of our design strategy was the classification of diseases and risk 123 
factors into either primary or secondary outcomes, which we defined on the basis of a priori 124 
statistical power to detect associations with telomere length. Primary outcomes were defined 125 
as diseases with sufficient cases and controls for >50% power (i.e. moderate-to-high 126 
statistical power) and secondary outcomes defined as diseases with <50% power (i.e. low 127 
statistical power) to detect RGGVUDWLRVSHUVWDQGDUGGHYLDWLRQLQFUHDVHLQWHORPHUHOHQJWK 128 
(alpha assumed to be 0.01). All risk factors were defined as secondary outcomes. Risk factors 129 
with low statistical power were excluded from all analyses. Further details on the power 130 
calculations and the study design are provided in the supplementary methods.  131 
 132 
Comparison with prospective observational studies 133 
We searched PubMed for prospective observational studies of the association between 134 
telomere length and disease (see Tables S3 and S4 for details of the search strategy and 135 
inclusion criteria). Study-specific relative risks for disease per unit change or quantile 136 
comparison of telomere length were transformed to a standard deviation scale using 137 
previously described methods.24 Hazard ratios, risk ratios, and odds ratios were assumed to 138 
approximate the same measure of relative risk. Where multiple independent studies of the 139 
same disease were identified, these were combined by fixed effects meta-analysis, unless 140 
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there was strong evidence of between-study heterogeneity (P&RFKUDQ¶V4<0.001), in which case 141 
they were kept separate.  142 
 143 
Statistical analysis 144 
We combined summary data across SNPs into a single genetic risk score, using maximum 145 
likelihood to estimate the slope of the relationship between ȕGD and ȕGP and a variance-146 
covariance matrix to make allowance for linkage disequilibrium between SNPs,25 ZKHUHȕGD 147 
is the change in disease or risk factor SHUFRS\RIWKHHIIHFWDOOHOHDQGȕGP is the standard 148 
deviation change in telomere length per copy of the effect allele (see supplementary methods 149 
for technical details). The slope from this approach can be interpreted as the log odds ratio for 150 
binary outcomes, or the unit change for continuous risk factors, per standard deviation change 151 
in genetically longer telomeres. P values for heterogeneity in the estimated associations 152 
between telomere length and disease amongst SNPs were estimated by likelihood ratio 153 
tests.25 Associations between genetically longer telomeres and continuous risk factors were 154 
transformed into standard deviation units. For six diseases where only a single SNP was 155 
available for analysis, we estimated associations using the Wald ratio: ȕGDȕGP, with standard 156 
errors approximated by the delta method.26  157 
Inference of causality in the estimated etiological associations between telomere length and 158 
disease depends on satisfaction of Mendelian randomization assumptions.27,28 The 159 
assumptions are: 1) the genetic proxies must be associated with telomere length; 2) the 160 
genetic proxies should not be associated with confounders; and 3) the genetic proxies must be 161 
associated with disease exclusively through their effect on telomere length. When these 162 
assumptions are satisfied, genetic proxies are said to be valid instrumental variables. We 163 
modeled the impact of violations of these assumptions through two sets of sensitivity 164 
analyses: a weighted median function29 and MR-Egger regression27 (see supplementary 165 
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methods for technical details). We restricted our sensitivity analyses to diseases showing the 166 
strongest evidence of association with genetically longer telomeres (defined as 167 
PBonferroni<0.05).  168 
 169 
We used meta-regression to appraise potential sources of clinical heterogeneity in our 170 
findings for cancer outcomes. The association of genetically longer telomeres with the log 171 
odds of cancer was regressed on cancer incidence, survival time and median age at diagnosis, 172 
downloaded from the National Cancer Institute Surveillance, Epidemiology, and End Results 173 
(SEER) Program,30 and tissue-specific rates of stem cell division from Tomasetti and 174 
Vogelstein.31 As the downloaded cancer characteristics from SEER correspond to the United 175 
States population, 77% of which was of white ancestry in 201532, the meta-regression 176 
analyses excluded genetic studies conducted in East Asian populations. 177 
 178 
All analyses were performed in R version 3.1.233 and Stata release 13.1 (StataCorp, College 179 
Station, TX). P values were two-sided and evidence of association was declared at P<0.05. 180 
Where indicated, Bonferroni corrections were used to make allowance for multiple testing, 181 
although this is likely to be overly conservative given the non-independence of many of the 182 
outcomes tested.  183 
 184 
 185 
 186 
 187 
 188 
 189 
 190 
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 191 
 192 
RESULTS  193 
 194 
We selected 16 SNPs as genetic proxies for telomere length (Fig. S1 & Table 1). The selected 195 
SNPs correspond to 10 independent genomic loci that collectively account for 2-3% of the 196 
variance in leukocyte telomere length, which is equivalent to an F statistic of ~18. This 197 
indicates that the genetic risk score, constructed from these 10 independent genomic loci, is 198 
strongly associated with telomere length (see supplementary discussion for a more detailed 199 
consideration).34 Summary data for the genetic proxies for telomere length were available for 200 
83 non-communicable diseases and 44 risk factors, corresponding to 409,819 cases (median 201 
2,092 per disease) and 1,404,633 controls (median 7,738 per disease) (Fig. S1, Table 2 and 202 
Table S1). The median number of SNPs available across disease datasets was 11 (min=1, 203 
max=13) and across risk factor datasets was 13 (min=10, max=13). Of the 83 diseases, 55 204 
were classified as primary outcomes and 28 as secondary outcomes (Table 2, Fig. S1 and 205 
Table S1).  206 
The results from primary analyses of non-communicable diseases are presented in Figure 1; 207 
results from secondary analyses of risk factors and diseases with low a priori power are 208 
presented in the supplementary materials (Fig. S2, S5 and S6). Genetically longer telomeres 209 
were associated with higher odds of disease for 9 of 22 primary cancer outcomes, including 210 
glioma, endometrial cancer, kidney cancer, testicular germ cell cancer, melanoma, bladder 211 
cancer, neuroblastoma, lung adenocarcinoma and serous low malignancy potential ovarian 212 
cancer (P<0.05) (Fig. 1). The associations were, however, highly variable across cancer 213 
types, varying from an odds ratio of 0.86 (95% confidence interval: 0.50 to 1.48) for head and 214 
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neck cancer to 5.27 (3.15, 8.81) for glioma. Substantial variability was also observed within 215 
tissue sites. For example, the odds ratio for lung adenocarcinoma was 3.19 (2.40 to 4.22) 216 
compared to 1.07 (0.82 to 1.39) for squamous cell lung cancer. For serous low malignancy 217 
potential ovarian cancer the odds ratio was 4.35 (2.39 to 7.94) compared to odds ratios of 218 
1.21 (0.87 to 1.68) for endometrioid ovarian cancer, 1.12 (0.938 to 1.34) for serous invasive 219 
ovarian cancer, 1.04 (0.66 to 1.63) for clear cell ovarian cancer and 1.04 (0.732 to 1.47) for 220 
mucinous ovarian cancer. The strongest evidence of association was observed for glioma, 221 
lung adenocarcinoma, neuroblastoma and serous low malignancy potential ovarian cancer 222 
(PBonferroni<0.05). Results for glioma and bladder cancer showed evidence for replication in 223 
independent datasets (independent datasets were not available for other cancers) (Fig. S3). 224 
Genetically longer telomeres were associated with reduced odds of disease for 6 of 32 225 
primary non-neoplastic diseases, including coronary heart disease, abdominal aortic 226 
aneurysm, Alzheimer's disease, celiac disease, interstitial lung disease and type 1 diabetes 227 
(P<0.05) (Figure 1). The strongest evidence of association was observed for coronary heart 228 
disease, abdominal aortic aneurysm, celiac disease and interstitial lung disease 229 
(PBonferroni<0.05). The associations with coronary heart disease and interstitial lung disease 230 
showed evidence for replication in independent datasets (Fig. S3).  231 
 232 
Our genetic findings were generally similar in direction and magnitude to estimates based on 233 
observational prospective studies of leukocyte telomere length and disease (Figure 3). Our 234 
genetic estimates for lung adenocarcinoma, melanoma, kidney cancer and glioma, were, 235 
however, stronger in comparison to observational estimates.  236 
 237 
In sensitivity analyses, we appraised the potential impact of confounding by pleiotropic 238 
pathways on our results. Associations estimated by the weighted median approach were 239 
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broadly similar to the main results for glioma, lung adenocarcinoma, serous low malignancy 240 
potential ovarian cancer, neuroblastoma, abdominal aortic aneurysm, coronary heart disease, 241 
interstitial lung disease and celiac disease (Fig. S4). In the second set of sensitivity analyses, 242 
implemented by MR-Egger regression, we found little evidence for the presence of pleiotropy 243 
3) (Fig. S4). The MR-Egger analyses were, however, generally underpowered, as 244 
reflected by the wide confidence intervals in the estimated odds ratios.  245 
 246 
In meta-regression analyses, we observed that genetically longer telomeres tended to be more 247 
strongly associated with rarer cancers (P=0.02) and cancers at tissue-sites with lower rates of 248 
stem cell division (P=0.02) (Figure 2). The associations showed little evidence of varying by 249 
percentage survival five years after diagnosis or median age-at-diagnosis (P=0.4). 250 
 251 
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DISCUSSION 252 
 253 
Summary of main findings 254 
In this report we show that genetically longer telomeres are associated with increased risk 255 
of several cancers and with reduced risk of some non-neoplastic diseases, including 256 
coronary heart disease, abdominal aortic aneurysm, celiac disease and interstitial lung 257 
disease. The findings for cancer were, however, subject to substantial variation between 258 
and within tissue sites, which our results suggest could be partly attributable to 259 
differences in cancer incidence and rates of stem cell division. Given the random 260 
distribution of genotypes in the general population with respect to lifestyle and other 261 
environmental factors, as well as the fixed nature of germline genotypes, these results 262 
should be less susceptible to confounding and reverse causation bias in comparison to 263 
observational studies. Nevertheless, although compatible with causality, our results could 264 
reflect violations of Mendelian randomization assumptions, such as confounding by 265 
pleiotropic pathways, population stratification or ancestry.35 Although we cannot entirely 266 
rule out this possibility, the majority of our results persisted in sensitivity analyses that 267 
made allowance for violations of Mendelian randomization assumptions. Confounding by 268 
population stratification or ancestry is also unlikely, given that the disease GWAS results 269 
were generally adjusted for both (see supplementary discussion).  270 
 271 
Comparison with previous studies 272 
Our findings for cancer are generally contradictory to those based on retrospective studies, 273 
which tend to report increased risk for cancer in individuals with shorter telomeres.9,10,36±39 274 
The contradictory findings may reflect reverse causation bias in the retrospective studies, 275 
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whereby shorter telomeres arise as a result of disease, or of confounding effects, e.g. due to 276 
cases being slightly older than controls even in age-matched analyses. Our findings for cancer 277 
are generally more consistent with those based on prospective observational studies, which 278 
tend to report weak or null associations of longer leukocyte telomeres with overall and site-279 
specific risk of cancer8±11,38,40±59 with some exceptions.60 Our results are also similar to 280 
previously reported Mendelian randomization studies of telomere length and risk of 281 
melanoma, lung cancer, chronic lymphocytic leukemia and glioma.61±64 The shape of the 282 
association with cancer may not, however, be linear over the entire telomere length 283 
distribution. For example, individuals with dyskeratosis congenita, a disease caused by 284 
germline loss-of-function mutations in the telomerase component genes TERC and TERT, 285 
have chronically short telomeres and are at increased risk of some cancers, particularly acute 286 
myeloid leukemia and squamous cell carcinomas arising at sites of leukoplakia,65,66 287 
VXJJHVWLQJWKDWWKHDVVRFLDWLRQFRXOGEH³-´RU³8´shaped.41,54 Our results should therefore 288 
be interpreted as reflecting the average association at the population level and may not be 289 
generalizable to the extreme ends of the distribution.  290 
 291 
Mechanisms of association 292 
Our cancer findings are compatible with known biology.67 By limiting the proliferative 293 
potential of cells, telomere shortening may serve as a tumour suppressor; and individuals with 294 
longer telomeres may be more likely to acquire somatic mutations owing to increased 295 
proliferative potential.67 Rates of cell division are, however, highly variable amongst tissues31 296 
and thus the relative gain in cell proliferative potential, conferred by having longer telomeres, 297 
may also be highly variable across tissues. This could explain the almost 9-fold variation in 298 
odds ratios observed across cancer types in the present study, as well as the tendency of our 299 
results to be stronger at tissue sites with lower rates of stem cell division. For example, the 300 
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association was strongest for glioma (OR=5.27) and comparatively weak for colorectal 301 
cancer (OR=1.09) and the rates of stem cell division in the tissues giving rise to these cancers 302 
differ by several orders of magnitude. In neural stem cells, which give rise to gliomas, the 303 
number of divisions is ~270 million and for colorectal stem cells is ~1.2 trillion over the 304 
average lifetime of an individual.31 The observation that genetically longer telomeres were 305 
more strongly associated with rarer cancers potentially reflects the same mechanism, since 306 
rarer cancers also tend to show lower rates of stem cell division.31 For example, the incidence 307 
of glioma is 0.4 and for colorectal cancer is 42.4 per 100,000 per year in the United States.30 308 
On the other hand, individuals with chronically short telomeres, such as those with 309 
dyskeratosis congenita, could be more susceptible to genome instability and chromosomal 310 
end-to-end fusions, which could underlie their increased susceptibility to cancer.65±67  311 
The inverse associations observed for some non-neoplastic diseases may reflect the impact of 312 
telomere shortening on tissue degeneration and an evolutionary trade-off for greater 313 
resistance to cancer at the cost of greater susceptibility to degenerative diseases, particularly 314 
cardiovascular diseases.68,69  315 
 316 
Study limitations 317 
Our study is subject to some limitations, in addition to the Mendelian randomization 318 
assumptions already considered above. First, our method assumes that the magnitude of the 319 
association between SNPs and telomere length is consistent across tissues. Second, our study 320 
assumed a linear shape of association between telomere length and disease risk, whereas the 321 
VKDSHFRXOGEH³-´RU³8´VKDSHG41,54,65 Third, our results assume that the samples used to 322 
define the genetic proxies for telomere length16 and the various samples used to estimate the 323 
SNP-disease associations are representative of the same general population, practically 324 
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defined as being of similar ethnicity, age and sex distribution.70 This assumption would, for 325 
example, not apply in the case of the SNP-disease associations derived from East Asian or 326 
pediatric populations. Generally speaking, violation of the aforementioned assumptions 327 
would potentially bias the magnitude of the estimated association between genetically longer 328 
telomeres and disease; but would be unlikely to increase the likelihood of false positives (i.e. 329 
incorrectly inferring an association when none exists).71 Our results should therefore remain 330 
informative for the direction and broad magnitude of the average association at the 331 
population level, even in the presence of such violations. Fourth, we cannot rule out chance in 332 
explaining some of the weaker findings. Fifth, our results may not be fully representative of 333 
non-communicable diseases (since not all studies shared data and our analyses were 334 
underpowered for the secondary disease outcomes). The diseases represented in our primary 335 
analyses probably account for >60% of all causes of death in American adults.72  336 
 337 
Clinical relevance of findings 338 
Our findings suggest that any potential clinical applications of telomere length, e.g. as a tool 339 
for risk prediction or as an intervention target for disease prevention, will have to consider a 340 
trade-off in risk between cancer and non-neoplastic diseases. For example, a number of 341 
Wellness companies have been established that offer telomere length measurement services 342 
to the public (via a requesting physician) claiming that shorter telomeres are a general 343 
indicator of poor health status, older biological age and that information on telomere length 344 
can be used to motivate healthy lifestyle choices in patients. The conflicting direction of 345 
association between telomere length and risk of cancer and non-neoplastic diseases suggests, 346 
however, that such services to the general public may be premature.   347 
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Conclusion 348 
Genetically longer telomeres are associated with increased risk for several cancers, but the 349 
relative increase in risk is highly heterogeneous across cancer types, and with reduced risk for 350 
some non-neoplastic diseases, including cardiovascular diseases. Further research is required 351 
to resolve whether telomere length is a useful predictor of risk that can help guide lifestyle 352 
modification, to clarify the shape of any dose-response relationship, and to characterise the 353 
nature of the association in population subgroups.  354 
 355 
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Table 1. Single nucleotide polymorphisms used as genetic proxies for telomere length 
*Summary data from Mangino et al16; Chr, chromosome; pos, base-pair position (GRCh38.p3); EA, effect allele, OA, other allele, Beta, standard deviation change in telomere length per 
copy of the effect allele; SE, standard error; EAF - effect allele frequency; Phet - p value for between-sWXG\KHWHURJHQHLW\LQDVVRFLDWLRQEHWZHHQ613DQGWHORPHUHOHQJWKIURPDPHWD-
analysis of Mangino16 and Gu18 performed in the present study. 
 
 
SNPs Chr Pos Gene EA OA EAF* Beta* SE* P-value* Phet* 
No. 
studies* 
Sample 
size* 
Discovery 
p-value 
% variance 
explained Discovery study 
rs11125529 2 54248729 ACYP2 A C 0.16 0.065 0.012 0.000606 0.313 6 9177 8.00E-10 0.080 Codd19 
rs6772228 3 58390292 PXK T A 0.87 0.041 0.014 0.049721 0.77 6 8630 3.91E-10 0.200 Pooley15 
rs12696304 3 169763483 TERC C G 0.74 0.090 0.011 5.41E-08 0.651 6 9012 4.00E-14 0.319 Codd20 
rs10936599 3 169774313 TERC C T 0.76 0.100 0.011 1.76E-09 0.087 6 9190 3.00E-31 0.319 Codd19 
rs1317082 3 169779797 TERC A G 0.71 0.097 0.011 4.57E-09 0.029 6 9176 1.00E-08 0.319 Mangino16 
rs10936601 3 169810661 TERC C T 0.74 0.087 0.011 8.64E-08 0.433 6 9150 4.00E-15 0.319 Pooley15 
rs7675998 4 163086668 NAF1 G A 0.80 0.048 0.012 0.008912 0.077 6 9161 4.35E-16 0.190 Codd19 
rs2736100 5 1286401 TERT C A 0.52 0.085 0.013 2.14E-05 0.54 4 5756 4.38E-19 0.310 Codd19 
rs9419958 10 103916188 OBFC1 T C 0.13 0.129 0.013 5.26E-11 0.028 6 9190 9.00E-11 0.171 Mangino16 
rs9420907 10 103916707 OBFC1 C A 0.14 0.142 0.014 1.14E-11 0.181 6 9190 7.00E-11 0.171 Codd19 
rs4387287 10 103918139 OBFC1 A C 0.14 0.120 0.013 1.40E-09 0.044 6 8541 2.00E-11 0.171 Levy23 
rs3027234 17 8232774 CTC1 C T 0.83 0.103 0.012 2.75E-08 0.266 6 9108 2.00E-08 0.292 Mangino16 
rs8105767 19 22032639 ZNF208 G A 0.25 0.064 0.011 0.000169 0.412 6 9096 1.11E-09 0.090 Codd19 
rs412658 19 22176638 ZNF676 T C 0.35 0.086 0.010 1.83E-08 0.568 6 9156 1.00E-08 0.484 Mangino16 
rs6028466 20 39500359 DHX35 A G 0.17 0.058 0.013 0.003972 0.533 6 9190 2.57E- 0.041 Mangino16 & Gu18 
rs755017 20 63790269 ZBTB46 G A 0.17 0.019 0.0129 0.339611 0.757 5 8026 6.71E-09 0.090 Codd19 
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Table 2. Study characteristics for primary non-communicable diseases  
  
No. 
cases 
No. 
controls 
No.  
SNPs 
Statistical 
power Pop. Study / First author 
Cancer             
Bladder cancer 1601 1819 10 0.62 EUR NBCS75 
Breast cancer  48155 43612  13  1.00  EUR  BCAC15,76  
Estrogen receptor ±ve 7465 42175 13 1.00 EUR BCAC15,76 
Estrogen receptor +ve 27074 41749 13 1.00 EUR BCAC15,76 
Colorectal cancer 14537 16922 9 1.00 EUR CORECT/GECC61,77 
Endometrial cancer 6608 37925 12 1.00 EUR ECAC78,79 
Esophageal SCC 1942 2111 11 0.64 EA Abnet80 
Glioma 1130 6300 12 0.72 EUR Wrensch81 & Walsh63  
Head & neck cancer 2082 3477 12 1.00 EUR McKay et al82 
Kidney cancer 2461 5081 12 0.99 EUR KIDRISK83 
Lung cancer 11348   15861 13  1.00  EUR  ILCCO84  
Adenocarcinoma 3442 14894 13 1.00 EUR ILCCO84 
Squamous cell carcinoma 3275 15038 13 1.00 EUR ILCCO84 
Skin cancer             
Melanoma 15976 26451 13 1.00 EUR MC85 
Basal cell carcinoma 3361 11518 13 1.00 EUR NHS/HPFS86  
Neuroblastoma 2101 4202 12 0.87 EUR Diskin87 
Ovarian cancer 15397   30816  13 1.00  EUR  OCAC15,88  
Clear cell 1016 30816 13 0.76 EUR OCAC15,88 
Endometriod 2154 30816 13 0.98 EUR OCAC15,88 
Mucinous 1643 30816 13 0.94 EUR OCAC15,88 
Serous invasive 9608 30816 13 1.00 EUR OCAC15,88 
Serous LMP 972 30816 13 0.73 EUR OCAC15,88 
Pancreatic cancer 5105 8739 12 1.00 EUR PanScan (incl. EPIC)89 
Prostate cancer 22297 22323 11 1.00 EUR PRACTICAL90,91 
Testicular germ cell cancer 986 4946 11 0.52 EUR Turnbull92 & Rapley93 
Autoimmune/inflammatory diseases  
Alopecia areata 2332 5233 7 0.60 EUR Betz94 
Atopic dermatitis 10788 30047 13 1.00 EUR EAGLE95 
Celiac disease 4533 10750 3 0.82 EUR Dubois96 
Inflammatory bowel disease             
Crohn's disease 5956 14927 11 1.00 EUR IIBDGC97 
Ulcerative colitis 6968 20464 12 1.00 EUR IIBDGC97 
Juvenile idiopathic arthritis 1866 14786 11 0.87 EUR Thompson98 
Multiple sclerosis 14498 24091 3 1.00 EUR IMSGC99 
Aggressive periodontitis 888 6789 13 0.63 EUR Schaefer100  
Rheumatoid arthritis 5538 20163 11 1.00 EUR Stahl101 
Cardiovascular diseases             
Abdominal aortic aneurysm 4972 99858 13 1.00 EUR AC102±107 
Coronary heart disease 22233 64762 13 1.00 EUR CARDIoGRAM108 
Heart failure 2526 20926 13 0.99 EUR CHARGE-HF109 
Hemorrhagic stroke 2963 5503 12 0.96 EUR METASTROKE/ISGC110  
Ischemic stroke  12389 62004  13  1.00  EUR  METASTROKE/ISGC111,112  
large vessel disease 2167 62004 13 0.99 EUR METASTROKE/ISGC111,112 
small vessel disease 1894 62004 13 0.97 EUR METASTROKE/ISGC111 
cardioembolic 2365 62004 13 0.99 EUR METASTROKE/ISGC111 
Sudden cardiac arrest 3954 21200 13 1.00 EUR Unpublished 
Diabetes             
Type 1 diabetes 7514 9045 6 0.95 EUR T1Dbase113 
Type 2 diabetes 10415 53655 11 1.00 EUR DIAGRAM114 
Eye disease             
AMD 7473 51177 13 1.00 EUR AMD Gene115 
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Retinopathy 1122 18289 12 0.75 EUR Jensen116  
Lung diseases             
Asthma 13034 20638 4 1.00 EUR Ferreira/GABRIEL117,118 
COPD 2812 2534 12 0.85 EUR COPDGene119 
Interstitial lung disease 1616 4683 9 0.60 EUR Fingerlin120  
Neurological / psychiatric diseases  
ALS 6100 7125 12 1.00 EUR SLAGEN/ALSGEN121 
Alzheimer's disease 17008 37154 12 1.00 EUR IGAP122 
Anorexia nervosa 2907 14860 9 0.93 EUR GCAN123 
Autism 4949 5314 7 0.82 EUR PGC124 
Bipolar disorder 7481 9250 9 1.00 EUR PGC125 
Major depressive disorder 9240 9519 8 0.99 EUR PGC126 
Schizophrenia 35476 46839 12 1.00 EUR PGC127 
Tourette syndrome 1177 4955 13 0.74 EUR Scharf128  
    Other       
Chronic kidney disease 5807 56430 13 1.00 EUR CKDGen129 
Endometriosis 4604 9393 11 1.00 Mix Nyholt130  
Study acronyms: AC, the aneurysm consortium; ALSGEN, the International Consortium on Amyotrophic Lateral Sclerosis Genetics; AMD Gene, 
Age-related Macular Degeneration Gene Consortium; BCAC, Breast Cancer Association Consortium; CARDIoGRAM, Coronary ARtery DIsease 
Genome wide Replication and Meta-analysis; CHARGE-HF, Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium ± Heart 
Failure Working Group; COPDGene, the genetic epidemiology of COPD; CKDGen, Chronic Kidney Disease; CORECT, ColoRectal 
Transdisciplinary Study; DIAGRAM, DIAbetes Genetics Replication And Meta-analysis; EAGLE, EArly Genetics & Lifecourse Epidemiology 
Eczema Consortium (excluding 23andMe); ECAC, Endometrial Cancer Association Consortium; GCAN, Genetic Consortium for Anorexia Nervosa; 
GECCO, Genetics and Epidemiology of Colorectal Cancer Consortium; IGAP, International Genomics of Alzheimer's Project; HPFS, Health 
Professionals Follow-Up Study; ILCCO, International Lung Cancer Consortium; IMSGC, International Multiple Sclerosis Genetic Consortium; 
IIBDGC, International Inflammatory Bowel Disease Genetics Consortium; KIDRISK, Kidney cancer consortium; MC, the melanoma meta-analysis 
consortium; METASTROKE/ISGC, METASTROKE project of the International Stroke Genetics Consortium; NBCS, Nijmegen Bladder Cancer 
Study; NHS, 1XUVHV¶ +HDOWK 6WXG\ OCAC, Ovarian Cancer Association Consortium; NCCC, Dartmouth-Hitchcock Norris Cotton Cancer Center; 
PANSCAN, Pancreatic Cancer Cohort Consortium; PGC, Psychiatric Genomics Consortium; PRACTICAL, Prostate Cancer Association Group to 
Investigate Cancer Associated Alterations in the Genome; SLAGEN, Italian Consortium for the Genetics of Ayotrophic Lateral Sclerosis. 
Abbreviations: ALS, amyotrophic lateral sclerosis; AMD, age-related macular degeneration; COPD, chronic obstructive pulmonary disease; EUR, 
European; EA, East Asian; LMP, low malignant potential; No., number; Pop., population; SCC, squamous cell carcinoma; SNP, single nucleotide 
polymorphism; -ve, negative; +ve, positive; plus previously unpublished data.  
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Figure 1. The association between genetically longer telomeres and odds of primary 
non-communicable diseases 
 
Legend to Figure 1 
 
*P value for association between genetically longer telomeres and disease from maximum likelihood; the effect estimate for heart failure is 
a hazard ratio (all others are odds ratios); Phet, p value for heterogeneity amongst SNPs in the genetic risk score; SNP, single nucleotide 
polymorphism; CI, confidence interval; LMP, low malignancy potential; ER, estrogen receptor; -VE, negative; +VE, positive.  
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Figure 2. The association between genetically longer telomeres and odds of cancer as a 
function of selected characteristics  
 
 
 
Legend to Figure 2 
 
The plotted data show how the strength of the relationship between genetically longer telomeres and cancer varies by the selected 
characteristic. The R2 statistic indicates how much of the variation between cancers can be explained by the selected characteristic. P values 
are from meta-regression models. Circle sizes are proportional to the inverse of the variance of the log odds ratio. The hashed line indicates 
the null of no association between telomere length and cancer (i.e. an odds ratio of 1). Data for percentage survival 5 years after diagnosis, 
cancer incidence and median age-at-diagnosis was downloaded from the Surveillance, Epidemiology, and End Results Program.30 Data for 
average lifetime number of stem cell divisions was downloaded from Tomasetti and Vogelstein.31 SD, standard deviation; OR, Odds ratio. 
Not all cancers had information available for the selected characteristics (hence the number of cancers varies across the subplots). 
Information was available for 12 cancers for tissue-specific rates of stem cell division, 18 cancers for percentage surviving 5 years post-
diagnosis, 23 cancers for cancer incidence and 18 cancers for median age-at-diagnosis.   
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Figure 3. Comparison of genetic and prospective observational studies of the association 
between telomere length and disease 
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Legend to Figure 3 
 
*from fixed-effects meta-analysis of independent observational studies described in Table S3; search strategy and characteristics for 
observational studies are described in Tables S3 and S4; Á&&+6DQG&*36; +PLCO, ATBC & SWHS (acronyms explained in Table S3); 
CI, confidence interval 
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